Drug Information

Drug General Information
Drug ID
D0I2YV
Former ID
DIB013351
Drug Name
BIBB-515
Drug Type
Small molecular drug
Indication Arteriosclerosis [ICD9: 440; ICD10:I70] Terminated [534359]
Company
Dr Karl Thomae GmbH
Formula
C22H21ClN2O2
Canonical SMILES
C(=O)(N1CCC(=Cc2ccc(C3=NCCO3)cc2)CC1)c1ccc(cc1)Cl
CAS Number
CAS 156635-05-1
PubChem Compound ID
501398
Target and Pathway
Target(s) Lanosterol synthase Target Info Modulator [526088], [534359]
BioCyc Pathway Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)
Cholesterol biosynthesis III (via desmosterol)
Cholesterol biosynthesis I
Superpathway of cholesterol biosynthesis
Lanosterol biosynthesis
KEGG Pathway Steroid biosynthesis
Metabolic pathways
Biosynthesis of antibiotics
PANTHER Pathway Cholesterol biosynthesis
PathWhiz Pathway Steroid Biosynthesis
Reactome Cholesterol biosynthesis
Activation of gene expression by SREBF (SREBP)
WikiPathways Activation of Gene Expression by SREBP (SREBF)
SREBP signalling
Cholesterol Biosynthesis
Cholesterol biosynthesis
References
Ref 534359Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
Ref 526088Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
Ref 534359Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.